DUBLIN – Geneuro SA is getting $47 million in an up-front payment and research funding and could earn $408 million more in development and commercial milestones from a deal with Les Laboratoires Servier involving its first-in-class phase II multiple sclerosis (MS) antibody GNbAC1.